IPM Clinical Trials

IPM is a non-profit organization dedicated to developing HIV prevention products and multipurpose prevention technologies for women in developing countries. To that end, IPM and our research partners conduct clinical trials to evaluate the safety, acceptability and, ultimately, the efficacy of potential new products. Below is a list of research studies conducted to date or planned in the future.

DAPIVIRINE VAGINAL RING

TRIAL	DESCRIPTION	COUNTRIES	N*	STATUS
IPM 001	Dapivirine ring safety (Ring-001)	Belgium	12	Completed
IPM 008	Dapivirine ring safety (Ring-002)	Belgium	13	Completed
IPM 018	Dapivirine ring safety & PK (Ring 002 & 003)	Belgium	24	Completed
IPM 011	Placebo ring acceptability & safety	South Africa, Tanzania	170	Completed
IPM 024	Dapivirine ring safety & PK (Ring-004)	Belgium	16	Completed
IPM 013	Dapivirine ring safety & PK (Ring-004)	Belgium	48	Completed
IPM 015	Dapivirine ring safety (Ring-004)	Kenya, Malawi, South Africa, Tanzania	280	Completed
IPM 028	Drug-drug interaction (Ring-004)	Belgium	36	Data analysis
IPM 029	Male condom functionality (Ring-004)	United States	~70 couples	Data analysis
IPM 027 (The Ring Study)	Dapivirine ring long-term safety & efficacy (Ring-004)	South Africa, Uganda	1950	Ongoing
IPM 007	Seroconverter protocol	South Africa; Uganda	n/a	Ongoing
IPM 033	Female condom functionality (Ring-004)	United States	~80 couples	Ongoing
IPM 034	Dapivirine ring release profile PK (Ring-004)	Belgium	40	Ongoing

DAPIVIRINE-MARAVIROC COMBINATION VAGINAL RING

MTN-013 / IPM 026	Maraviroc ring, dapivirine ring, and dapivirine-maraviroc ring PK & safety	United States	48	Completed

DAPIVIRINE VAGINAL GEL

IPM 003	Dapivirine gel safety & PK (Gel-002)	Rwanda, South Africa, Tanzania	112	Completed
IPM 004	Dapivirine gel PK (Gel-002)	South Africa	18	Completed
IPM 005B	Dapivirine gel safety (Gel-002)	Belgium	36	Completed
IPM 012	Dapivirine gel PK & safety (Gels 4750 & 4789)	Belgium	36	Completed
IPM 020	Dapivirine gel safety (Gels 4759 & 4789)	United States	128	Completed
IPM 014A	Dapivirine gel safety & acceptability (Gel 4759)	Kenya, Malawi, Rwanda, South Africa	280	Completed
IPM 014B	Dapivirine gel safety & acceptability (Gel 4789)	South Africa	100	Completed
MTN-012 / IPM 010	Dapivirine gel male tolerance (Gel 4759)	United States	48 men	Completed

NOTE: The first Phase I safety trial of dapivirine gel (Gel-001) was conducted by Tibotec Pharmaceuticals among 52 women in Belgium.

* Estimated number of enrolled clinical trial participants (participants in all trials are women, except where otherwise noted).